Get started
Author

Douglas Weston Sborov

Observed names: D. Sborov, D. W. Sborov, D.W. Sborov, D.W. Sborov, DOUGLAS W. SBOROV, Douglas Sborov, Douglas W Sborov, Douglas W. Sborov, Sborov, Douglas W.
Observed institutions: University of Utah, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Tata Memorial Hospital, Huntsman Cancer Institute, The Ohio State University Wexner Medical Center, Dana-Farber Cancer Institute, University of Utah Health Care, The Ohio State University
ORCID: 0000-0003-4268-2698
Observed ORCID: 0000-0003-4268-2698
OpenAlex ID: A5053731124
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
2019 · Sagar Lonial, Hans C Lee, et al. · The Lancet Oncology · 828
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
2020 · Peter M. Voorhees, Jonathan L. Kaufman, et al. · Blood · 716
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
2023 · Doris K. Hansen, Surbhi Sidana, et al. · Journal of Clinical Oncology · 305
PDF
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
2020 · Shaji K. Kumar, Natalie S. Callander, et al. · Journal of the National Comprehensive Cancer Network · 281
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022
2022 · Natalie S. Callander, Muhamed Baljevic, et al. · Journal of the National Comprehensive Cancer Network · 220
Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
2020 · Asim V. Farooq, Simona Degli Esposti, et al. · Ophthalmology and Therapy · 184
PDF
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial
2023 · Peter M Voorhees, Douglas W Sborov, et al. · The Lancet Haematology · 181
PDF
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
2023 · Shaji K. Kumar, Natalie S. Callander, et al. · Journal of the National Comprehensive Cancer Network · 174
PDF
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
2024 · Surbhi Sidana, Krina K. Patel, et al. · Blood · 161
PDF
NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020
2019 · Shaji K. Kumar, Natalie S. Callander, et al. · Journal of the National Comprehensive Cancer Network · 161
PDF
Longer term outcomes with single‐agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13‐month follow‐up from the pivotal DREAMM‐2 study
2021 · Sagar Lonial, Hans C. Lee, et al. · Cancer · 147
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy
2023 · Christopher J. Ferreri, Michelle A. T. Hildebrandt, et al. · Blood Cancer Journal · 131
PDF
A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma
2014 · Douglas W. Sborov, Gerard J. Nuovo, et al. · Clinical Cancer Research · 94
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
2021 · Sagar Lonial, Ajay K. Nooka, et al. · Blood Cancer Journal · 91
PDF
Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
2020 · Domenico Viola, Ada Dona, et al. · Leukemia · 89
PDF
Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial
2023 · Zachary D. Crees, Michael P. Rettig, et al. · Nature Medicine · 87
PDF
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
2024 · Gliceida Galarza Fortuna, Rahul Banerjee, et al. · Blood Cancer Journal · 86
Single‐agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM‐2 trial
2023 · Ajay K. Nooka, Adam D. Cohen, et al. · Cancer · 79
PDF
Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study
2024 · Ashraf Badros, Laahn Foster, et al. · Blood · 72
PDF
Investigational cancer drugs targeting cell metabolism in clinical development
2014 · Douglas W Sborov, Bradley M Haverkos, et al. · Expert Opinion on Investigational Drugs · 72
Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials
2022 · Saurabh Chhabra, Natalie Callander, et al. · Transplantation and Cellular Therapy · 66
PDF
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
2025 · Doris K. Hansen, Lauren C. Peres, et al. · Journal of Clinical Oncology · 62
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
2024 · Saurabh Zanwar, Surbhi Sidana, et al. · Journal of Hematology & Oncology · 61
Financial toxicity in hematological malignancies: a systematic review
2022 · Evguenia Ouchveridze, Rahul Banerjee, et al. · Blood Cancer Journal · 60
PDF
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
2017 · Douglas W. Sborov, Alessandro Canella, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 60
Works count: 455
Citation count: 6,860
H-index: 39
I10-index: 103
Year
Topic
Type